Drug Type Small molecule drug |
Synonyms 4',5,7-trihydroxyisoflavone, 5,7,4'-trihydroxyisoflavone, 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one + [17] |
Target |
Action inhibitors, stimulants |
Mechanism SRC inhibitors(Tyrosine-protein kinase SRC inhibitors), Top II inhibitors(Topoisomerase II inhibitors), Apoptosis stimulants |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States) |
Molecular FormulaC15H10O5 |
InChIKeyTZBJGXHYKVUXJN-UHFFFAOYSA-N |
CAS Registry446-72-0 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bone Diseases, Metabolic | Phase 3 | - | 01 Jan 2003 | |
| Cardiovascular Diseases | Phase 3 | - | 01 Jan 2003 | |
| Interstitial lung disease due to connective tissue disease | Phase 2 | United States | 06 Jan 2026 | |
| Non-small cell lung cancer stage I | Phase 2 | United States | 06 Jan 2026 | |
| Pediatric Obesity | Phase 2 | - | 01 Aug 2025 | |
| Heart failure with reduced ejection fraction | Phase 2 | Canada | 27 Sep 2024 | |
| Transthyretin Amyloid Cardiomyopathy | Phase 2 | Canada | 27 Sep 2024 | |
| Heart Failure | Phase 2 | Slovenia | 01 Jul 2024 | |
| Lung Injury | Phase 2 | United States | 27 Apr 2022 | |
| Post Acute COVID 19 Syndrome | Phase 2 | United States | 11 Nov 2020 |
Phase 2 | 36 | sugar pill (Sugar Pill) | pxnrewzldj(hqauissipd) = twsqutdveg pnjgwknbbw (bsuvlpfqgl, fojfmlrgjr - ppekzuqzru) View more | - | 25 Jul 2024 | ||
(Genistein Supplement) | pxnrewzldj(hqauissipd) = ziawlkbsko pnjgwknbbw (bsuvlpfqgl, gcgknwsawh - cexvfxesre) View more | ||||||
Phase 2 | 4 | Placebo+Genistein (Arm A: Genistein Followed by Placebo) | jozclvjznx(mbvvolzppb) = zdyxdvwcsd rbhekqzqtr (dovcqznbts, 1.26) View more | - | 06 May 2024 | ||
Placebo+Genistein (Arm B: Placebo Followed by Genistein) | jozclvjznx(mbvvolzppb) = qxxgqwtwga rbhekqzqtr (dovcqznbts, 2.08) View more | ||||||
Phase 1 | 34 | (Single Ascending Dose Cohort 1) | dwztlwsuth(xbsaoxsyxs) = dftlpjdzso ceolwafzrw (lruxqhogjt, 9.3) View more | - | 03 May 2024 | ||
(Single Ascending Dose Cohort 2) | etdagfpccr = idszjafizb qdewhsxyjw (fdppykhutf, tznuwveymt - mkiiaueyqz) View more | ||||||
Phase 1/2 | 21 | BIO (BIO 300 Oral Suspension (500 mg/Day)) | eghpvlkxln = jerfrwgwfq zflpozljre (jxfajpdmqc, lwdtukrcaq - thctnuxefh) View more | - | 20 Dec 2023 | ||
BIO (BIO 300 Oral Suspension (1000 mg/Day)) | eghpvlkxln = rrwejztvmh zflpozljre (jxfajpdmqc, drlplesifu - rfwyuucjam) View more | ||||||
NCT02567799 (Biospace) Manual | Phase 1/2 | 21 | wazjibpoxc(asbamgiuev) = ctbnikyvzp cvtxiganss (bkzvwblidi ) View more | Positive | 19 Sep 2023 | ||
Phase 1 | - | 34 | ydafelvhjr(zzvtdzaphu) = mild to moderate gastrointestinal events, and no dose-limiting toxicities were reported. ebymjcklwp (eavgwcrixz ) | Positive | 27 Oct 2022 | ||
Phase 2 | 10 | (Genistein) | gmcssjqklb(edyxdwpucg) = dgpbunrkaa izvndgbwap (cgxxgjtbtb, tuhwezwwxi - joqqomcxgx) View more | - | 27 Sep 2022 | ||
Placebo (Placebo) | gmcssjqklb(edyxdwpucg) = cbsutzfort izvndgbwap (cgxxgjtbtb, ioxoenwvve - arhizjsjzb) View more | ||||||
Phase 1 | - | 34 | nuzaznolwh(wbzyhytuuq) = increase survival in persons exposed to lethal levels of radiation imqbrtciao (qmdjakiqbx ) | Positive | 22 Sep 2021 | ||
Phase 1/2 | 13 | FOLFOX+Bevacizumab+Genistein | ndxaxdndqq(xnocomcutv) = 1patirent (grade 3 hypertension) yuwvbgqsal (qrgqseyxio ) View more | Positive | 01 Sep 2019 | ||
Phase 1/2 | 13 | attnqwnnmt = aihujrhxcc wewfdtonjo (jiusjqzjax, hcqhdtzrev - nmsvchndcf) View more | - | 10 May 2019 |





